Nektar Therapeutics (NKTR.OQ)
NKTR.OQ on NASDAQ Stock Exchange Global Select Market
35.17USD
9:00pm BST
35.17USD
9:00pm BST
Change (% chg)
$1.47 (+4.36%)
$1.47 (+4.36%)
Prev Close
$33.70
$33.70
Open
$33.80
$33.80
Day's High
$35.43
$35.43
Day's Low
$33.80
$33.80
Volume
391,711
391,711
Avg. Vol
605,284
605,284
52-wk High
$69.71
$69.71
52-wk Low
$29.26
$29.26
About
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)
Overall
| Beta: | 2.74 |
| Market Cap(Mil.): | $5,874.15 |
| Shares Outstanding(Mil.): | 174.31 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NKTR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 9.56 | 103.73 | 36.81 |
| EPS (TTM): | 3.52 | -- | -- |
| ROI: | 53.05 | 7.70 | 12.05 |
| ROE: | 77.86 | 8.20 | 16.96 |
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Feb 15 Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.
Estimates